# Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

> **NCT00469729** · PHASE2,PHASE3 · COMPLETED · sponsor: **Gamida Cell -Teva Joint Venture Ltd.** · enrollment: 101 (actual)

## Conditions studied

- Hematologic Malignancies
- Acute Myeloid Leukemia
- Lymphoid Leukemia
- Chronic Myeloid Leukemia
- Hodgkin's Disease
- Non-Hodgkin's Lymphoma
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** StemEx®

## Key facts

- **NCT ID:** NCT00469729
- **Lead sponsor:** Gamida Cell -Teva Joint Venture Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2013-02
- **Final completion:** 2015-06
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2015-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469729, "Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00469729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*